Employees: 901
Size Shenzhen Weiguang Biological Products (002880.SZ) is a China Health Care company (Biotechnology) with a market value of $633M, the 3122nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.87 on 18 Nov 2026.
Performance Over six months the shares fell 26.8%, against -12.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue fell 0.4% over the last twelve months (peer median +23.1%); the operating margin is 17.9% (peer median -130.4%).
Valuation It trades at 19.2× forward earnings against a peer median of 24.0× (2nd cheapest of 6).
Capital Return on invested capital runs 2.1 points above its cost of capital (5.3% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.13B | CN¥1.26B | CN¥1.20B | CN¥1.04B | CN¥665M |
| Revenue growth | — | +5% | +15% | +57% | — |
| Gross profit | CN¥502M | CN¥468M | CN¥480M | CN¥413M | CN¥225M |
| EBITDA | n/a | CN¥445M | CN¥439M | CN¥328M | CN¥176M |
| Net income | CN¥170M | CN¥246M | CN¥254M | CN¥219M | CN¥118M |
| Free cash flow | -CN¥69.4M | CN¥108M | -CN¥75.6M | CN¥69.1M | -CN¥325M |
| Capital expenditure | CN¥108M | CN¥170M | CN¥256M | CN¥329M | CN¥327M |
| Total debt | CN¥833M | CN¥864M | CN¥697M | CN¥525M | CN¥547M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002880.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.2% | -13.1% | 9th highest of 21 |
| 6-month return | -26.8% | -12.9% | 7th lowest of 20 |
| Distance from 52-week high | -44.2% | -44.6% | 9th highest of 21 |
| Revenue growth (TTM) | -0.4% | +23.1% | 5th lowest of 17 |
| Operating margin | 17.9% | -130.4% | 2nd highest of 18 |
| Forward P/E | 19.2× | 24.0× | 2nd cheapest of 6 |
| ROIC minus cost of capital | +2.1 pp | -15.1 pp | 2nd highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 19.2× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 17.4× | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | n/a | -8.9% | -1.3% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | n/a | 40.3% | +21.5% |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 24.0× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | n/a | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | n/a | 44.8% | +14.7% |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | n/a | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 431.5× | 39.8% | +143.5% |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 69.3× | 31.9% | +27.2% |